What is a stock summary page? Click here for an overview.
Business Description
Fennec Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA31447P1009
Compare
Compare
Traded in other countries / regions
FRX.CanadaFENC.USARV41.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2002-01-28Description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.38 | |||||
| Equity-to-Asset | -0.13 | |||||
| Debt-to-Equity | -3.29 | |||||
| Debt-to-EBITDA | 4.33 | |||||
| Interest Coverage | 0.59 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -2.94 | |||||
| Beneish M-Score | 28.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 70.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 35.18 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.73 | |||||
| 9-Day RSI | 55.8 | |||||
| 14-Day RSI | 49.4 | |||||
| 3-1 Month Momentum % | 3.21 | |||||
| 6-1 Month Momentum % | 51.65 | |||||
| 12-1 Month Momentum % | -29.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.38 | |||||
| Quick Ratio | 6.22 | |||||
| Cash Ratio | 3.85 | |||||
| Days Inventory | 194.79 | |||||
| Days Sales Outstanding | 88.05 | |||||
| Days Payable | 468.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -1.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.28 | |||||
| Operating Margin % | 5.1 | |||||
| Net Margin % | -1.28 | |||||
| FCF Margin % | 56.75 | |||||
| ROA % | -1.15 | |||||
| ROIC % | 24.08 | |||||
| 3-Year ROIIC % | 269.07 | |||||
| ROC (Joel Greenblatt) % | 42.39 | |||||
| ROCE % | 8.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 84.03 | |||||
| PS Ratio | 3.17 | |||||
| Price-to-Free-Cash-Flow | 6.48 | |||||
| Price-to-Operating-Cash-Flow | 6.48 | |||||
| EV-to-EBIT | 35.06 | |||||
| EV-to-EBITDA | 29.09 | |||||
| EV-to-Revenue | 2.85 | |||||
| EV-to-Forward-Revenue | 2.83 | |||||
| EV-to-FCF | 5.11 | |||||
| Earnings Yield (Greenblatt) % | 2.85 | |||||
| FCF Yield % | 18.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FENC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fennec Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 47.538 | ||
| EPS (TTM) ($) | -0.06 | ||
| Beta | 0.97 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 59.18 | ||
| 14-Day RSI | 49.4 | ||
| 14-Day ATR ($) | 0.331366 | ||
| 20-Day SMA ($) | 5.426 | ||
| 12-1 Month Momentum % | -29.8 | ||
| 52-Week Range ($) | 3.96 - 10.0657 | ||
| Shares Outstanding (Mil) | 27.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fennec Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fennec Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fennec Pharmaceuticals Inc Frequently Asked Questions
What is Fennec Pharmaceuticals Inc(FENC)'s stock price today?
The current price of FENC is $5.63. The 52 week high of FENC is $10.07 and 52 week low is $3.96.
When is next earnings date of Fennec Pharmaceuticals Inc(FENC)?
The next earnings date of Fennec Pharmaceuticals Inc(FENC) is 2025-05-14 Est..
Does Fennec Pharmaceuticals Inc(FENC) pay dividends? If so, how much?
Fennec Pharmaceuticals Inc(FENC) does not pay dividend.
Guru Commentaries on NAS:FENC
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers